Clinical Trial Update: A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 study of ELI-002 in KRAS-mutated pancreatic ductal adenocarcinoma and other KRAS-driven solid tumors has completed enrollment, with results posted Janua…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma
• Colorectal Cancer
• Gallbladder Carcinoma
• Non-small Cell Lung Cancer
• Ovarian Cancer
• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• ELI-002

Snippet

Sponsor: Elicio Therapeutics | Conditions: Minimal Residual Disease, KRAS G12D | Phase 1 | Status: COMPLETED | Results posted: 2025-01-17